Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jul 5;27(Suppl 2):12–24. doi: 10.1002/clc.4960271404

Pathophysiology and therapeutic targets for ischemic stroke

Steven R Levine 1,✉
PMCID: PMC6654701  PMID: 15188932

Abstract

The increased risk for stroke among those who have had a previous stroke or transient ischemic attack (TIA) and the tremendous burden of disability among stroke sufferers make both primary and secondary preventative strategies imperative. An understanding of the pathophysiology of stroke and TIA can help identify appropriate therapeutic targets.

Full Text

The Full Text of this article is available as a PDF (176.1 KB).

References

  • 1. Rajamani K, Fisher M: An overview of atherosclerosis In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 324–329. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 2. Roberts WC: The coronary arteries in ischemic heart disease: Facts and fancies. Triangle 1977; 16: 77–90 [PubMed] [Google Scholar]
  • 3. Greenberg JH: Glucose and oxygen metabolism in ischemia In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 227–248. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 4. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA: Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33: 901–906 [DOI] [PubMed] [Google Scholar]
  • 5. Joint National Committee : The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 24: 2413–2446 [DOI] [PubMed] [Google Scholar]
  • 6. Elliott WJ, Bakris GL, McCampbell EL, Prisant LM: Diabetic hypertension. Ensuring optimal therapy in the primary‐care setting. Medical Crossfire. Available at: www.medicalcrossfire.com/debate_archive/Spec_Ed/DiabeticHypertension.htm. Accessed October 16, 2002.
  • 7. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ: AHA Scientific Statement. Primary prevention of ischemic stroke. Circulation 2001; 103: 163–182 [DOI] [PubMed] [Google Scholar]
  • 8. Scandinavian Simvastatin Survival Study Group : Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
  • 9. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 10. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ: Stroke, statins, and cholesterol. A meta‐analysis of randomized, placebo‐controlled, double‐blind trials with HMG‐CoA reductase inhibitors. Stroke 1997; 28: 946–950 [DOI] [PubMed] [Google Scholar]
  • 11. American Heart Association . Available at: www.americanheart.org. Accessed March 13, 2003.
  • 12. Sloan MA: Toxicity/substance abuse In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 413–416. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 13. Kittner SJ, Bush TL: Pregnancy, hormonal contraception, and post‐menopausal estrogen replacement therapy In Primer on Cerebro‐vascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 324–329. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 14. Women's Health Initiative Writing Group : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: First results of the WHI in the HT study. J Am Med Assoc 2002; 288: 321–333 [DOI] [PubMed] [Google Scholar]
  • 15. American Stroke Association . Available at www.strokeassocia‐tion.jhtm?identifier=1033. Accessed December 6, 2002.
  • 16. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett‐Connor E, Hulley SB, for the HERS Research Group : Postmeno‐pausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation 2001; 103: 638–642 [DOI] [PubMed] [Google Scholar]
  • 17. Viscou CM, Brass LM, Kernan WN, Sarrel PM, Suissa SM, Horwitz RI: A clinical trial of estrogen‐replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243–1249 [DOI] [PubMed] [Google Scholar]
  • 18. Kloner RA, Hale S, Alker K, Rezkalla S: The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85: 407–419 [DOI] [PubMed] [Google Scholar]
  • 19. Mohr JP, Albers GW, Amarenco P, Babikian VL, Biller J, Brey RL, Coull B, Easton JD, Gomez CR, Helgason CM, Kase CS, Pullicino PM, Turpie AGG: American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Etiology of stroke. Stroke 1997; 28: 1501–1506 [DOI] [PubMed] [Google Scholar]
  • 20. Hart RC, Albers GW, Koudstaal PJ: Cardioembolic stroke In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 1392–1429. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 21. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA: Risk factors. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Stroke 1997; 28: 1507–1517 [DOI] [PubMed] [Google Scholar]
  • 22. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983–988 [DOI] [PubMed] [Google Scholar]
  • 23. Helgason CM, Wolf PA: Executive summary. American Heart Association Prevention Conference IV: Prevention and rehabilitation of stroke. Circulation 1997; 96: 701–707 [DOI] [PubMed] [Google Scholar]
  • 24. Sacco RL: Current epidemiology of stroke In Current Review of Cerebrovascular Disease (Eds. Fisher M, Bogousslavsky J.), p. 3–14. Philadelphia, Pa.: Current Medicine, 1993. [Google Scholar]
  • 25. Mohr JP: Natural history and pathophysiology of brain infarction. Circulation 1991; 83 (suppl I): I‐172–I‐175 [PubMed] [Google Scholar]
  • 26. Sacco RL, Ellenberg JA, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA: Infarction of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 1989; 25: 382–390 [DOI] [PubMed] [Google Scholar]
  • 27. Tresser SJ, Selman WR, Ratcheson RA: Pathophysiological alterations following aneurysm rupture In Ruptured Cerebral Aneurysms: Perioperative Management. Vol. 6: Concepts in Neuro‐surgery (Eds. Ratcheson RA, Wirth FP.), p. 23–45. Baltimore, Md.: Williams and Wilkins, 1994. [Google Scholar]
  • 28. Chicoine MR, Dacey RG Jr: Clinical aspects of subarachnoid hemorrhage In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 425–432. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 29. Voelker JL, Kaufman HH: Clinical aspects of intracerebral hemorrhage In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 432–436. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 30. Broderick JP, Brott T, Tomsick T, Miller R, Huster G: Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993; 78: 188–191 [DOI] [PubMed] [Google Scholar]
  • 31. Sacco R. Ischemic stroke In Handbook of Neuroepidemiology (Eds. Gorelick PB, Alter M. ), p. 77–119. New York, N.Y.: Marcel Dekker, 1994. [Google Scholar]
  • 32. Mohr JP: Cryptogenic stroke. N Engl J Med 1988; 318: 1197–1198 [DOI] [PubMed] [Google Scholar]
  • 33. Heinzlef O, Cohen A, Amarenco P: An update on aortic causes of ischemic stroke. Curr Opin Neurol 1997; 10: 64–72 [DOI] [PubMed] [Google Scholar]
  • 34. Barbut D, Caplan LR: Cerebrovascular complications of cardiac surgery In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 783–786. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 35. Sawada T: Anterior cerebral artery and anterior communicating artery syndromes In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 986–996. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 36. Neau J‐PH, Bogousslavsky J: Middle cerebral artery syndromes In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 997–1027. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 37. Caplan LR, Bogousslavsky J: Posterior cerebral artery syndromes In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 1028–1056. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 38. Donnan GA, Yasaka M: Lacunes and lacunar syndromes In Cere‐brovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 1090–1102. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 39. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM: Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991; 22: 1236–1241 [DOI] [PubMed] [Google Scholar]
  • 40. Bernat JL: Systemic hypoperfusion brain injury In Primer on Cere‐brovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 289–292. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 41. Bladin CF, Chambers BR: Clinical features, pathogenesis, and computed tomographic characteristics of internal watershed infarction. Stroke 1993; 24: 1925–1932 [DOI] [PubMed] [Google Scholar]
  • 42. Bladin CF, Chambers BR: Frequency and pathogenesis of hemo‐dynamic stroke. Stroke 1994; 25: 2179–2182 [DOI] [PubMed] [Google Scholar]
  • 43. Albers GW: Transient ischemic attack—proposal for a new definition. N Engl J Med 2002; 21; 347: 1713–1716 [DOI] [PubMed] [Google Scholar]
  • 44. Carolei A, Marini C, Fieschi C: Transient ischemic attacks In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 941–960. Mal‐den, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 45. Ad Hoc Committee on Cerebrovascular Diseases : Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990; 21: 637–676 [DOI] [PubMed] [Google Scholar]
  • 46. Brown RD Jr, Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP: Incidence of transient ischemic attack in Rochester, Minnesota, 1985‐1989. Stroke 1998; 29: 2109–2113 [DOI] [PubMed] [Google Scholar]
  • 47. Johnston SC, Gress DR, Browner WS, Sidney S: Short‐term prognosis after emergency department diagnosis of TIA. J Am Med Assoc 2000; 284: 2901–2906 [DOI] [PubMed] [Google Scholar]
  • 48. Iannuzzi A, Wilcosky T, Mercuri M, Rubba P, Bryan FA, Bond MG: Ultrasonographic correlates of carotid atherosclerosis in transient ischemic attack and stroke. Stroke 1995; 26: 614–619 [DOI] [PubMed] [Google Scholar]
  • 49. Hollander M, Breteler MMB: Markers of subclinical vascular disease and stroke In The Prevention of Stroke (Eds. Gorelick PB, Alter M.), p. 105–114. New York, N.Y.: Parthenon Publishing Group, 2002. [Google Scholar]
  • 50. Strong JP: Atherosclerotic lesions. Natural history, risk factors, and topography. Arch Pathol Lab Med 1992; 116: 1268–1275 [PubMed] [Google Scholar]
  • 51. Rajamani K, Fisher M, Fisher M: Atherosclerosis, pathogenesis and pathophysiology In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 1308–1318. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 52. Pepine CJ: The effects of angiotensin‐converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial ischemia. Am J Cardiol 1998; 9 (suppl 2): 23S–27S [DOI] [PubMed] [Google Scholar]
  • 53. Becker RC: Antithrombotic therapy after myocardial infarction. N Engl J Med 2002; 347: 1019–1022 [DOI] [PubMed] [Google Scholar]
  • 54. Faraci FM, Heistad DD: Pathophysiologic mechanisms in cerebral blood vessels In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 333–342. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 55. Johansson BB: Hypertension In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 142–144. San Diego, Calif.: Academic Press, 1997: 142–144 [Google Scholar]
  • 56. Sawada K, Naiki M, Yago H, Matsushita K, Ohtsuki T, Kitagawa K, Matsumoto M, Masatsugu Hori: Hypertension associated with reduced plasma thrombomodulin levels and a hypercoagulable state in rats. Clin Exp Hypertens 2003; 25: 73–84 [DOI] [PubMed] [Google Scholar]
  • 57. Nishikawa T, Edelstein D, Brownlee M: The missing link: A single unifying mechanism for diabetic complications. Kidney Int 2000; 58 (suppl 77): S26–S30 [DOI] [PubMed] [Google Scholar]
  • 58. DeGraba TJ: Inflammation, infection and homocysteine in atherosclerosis In The Prevention of Stroke (Eds. Gorelick PB, Alter M.), p. 49–64. New York, N.Y.: Parthenon Publishing Group, 2002. [Google Scholar]
  • 59. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giuglianao D: Circulating adhesion molecules in humans: Role of hyperglycemia and hyperinsulinemia. Circulation 2000; 101: 2247–2251 [DOI] [PubMed] [Google Scholar]
  • 60. Ross R, Wight TN, Strandness E, Thiele B: Human atherosclerosis: I. Cell constituents and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol 1984; 114: 79–93 [PMC free article] [PubMed] [Google Scholar]
  • 61. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified low‐density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134–5138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low‐density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995–2998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Quinn MT, Parthasarathy S, Steinberg D: Endothelial cell‐derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low‐density lipoprotein. Proc Natl Acad Sci USA 1985; 82: 5949–5953 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Kugiyama K, Bucay M, Morrisett JD, Roberts R, Henry PD: Oxidized LDL impairs endothelium‐dependent arterial relaxation. Circulation 1989; 80 (suppl II): II‐279 [Google Scholar]
  • 65. Sacco RL, Elkind M, Boden‐Albala B, Lin I‐F, Kargman DE, Hauser WA, Shea S, Paik MC: The protective effect of moderate alcohol consumption on ischemic stroke. J Am Med Assoc 1999; 281: 53–60 [DOI] [PubMed] [Google Scholar]
  • 66. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone‐Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole JF, Greengold NL, Rhew DC: Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J Am Med Assoc 1999; 281: 1112–1120 [DOI] [PubMed] [Google Scholar]
  • 67. Sacco RL: Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology 1997; 49 (suppl 4): S39–S44 [DOI] [PubMed] [Google Scholar]
  • 68. Wolf PA: Cigarettes, alcohol, and stroke. N Engl J Med 1986; 315: 1087–1089 [DOI] [PubMed] [Google Scholar]
  • 69. Gorelick PB: Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An invited review. Stroke 2002; 33: 862–875 [DOI] [PubMed] [Google Scholar]
  • 70. Miller A, Mujumdar V, Shek E, Guillot J, Angelo M, Palmer L, Tyagi SC: Hyperhomocyst(e)inemia induces multiorgan damage. Heart Vessels 2000; 15: 135–143 [DOI] [PubMed] [Google Scholar]
  • 71. Feinberg WM, Coull BM: Coagulopathies and stroke In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 399–401. San Diego, Calif: Academic Press, 1997. [Google Scholar]
  • 72. Anderson LR, Feinberg WM: Primary platelet disorders In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 401–405. San Diego, Calif: Academic Press, 1997. [Google Scholar]
  • 73. Brey RL, Stallworth CL, McGlasson DL, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Sherwin R, Price TR, Macko RF, Johnson CJ, Earley CJ, Buchholz DW, Hebel JR, Kittner SJ: Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396–2400 [DOI] [PubMed] [Google Scholar]
  • 74. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ: β2‐glycoprotein 1‐dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The Honolulu Heart Program. Stroke 2001; 32: 1701–1706 [DOI] [PubMed] [Google Scholar]
  • 75. Siesjö BK, Kristian T, Katsura K‐I: Overview of bioenergetic failure and metabolic cascades in brain ischemia In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 3–13. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 76. Schmid‐Schonbein GW: Capillary plugging by granulocytes and no reflow phenomenon in the microcirculation. Federation Proc 1987; 46: 2397–2401 [PubMed] [Google Scholar]
  • 77. del Zoppo GJ: Microvascular changes during cerebral ischemia and reperfusion. Cerebrovasc Brain Metab Rev 1994; 6: 47–96 [PubMed] [Google Scholar]
  • 78. Feuerstein GZ, Liu T, Barone FC: Cytokines, inflammation, and brain injury: Role of tumor necrosis factor. Cerebrovasc Brain Metab Rev 1994; 6: 341–360 [PubMed] [Google Scholar]
  • 79. Hallenbeck J: Inflammatory reactions at the blood‐endothelial interface in acute stroke In Advances in Neurology (Eds. Siesjo B, Wieloch T.), p. 281–296. New York: Raven Press, 1996. [PubMed] [Google Scholar]
  • 80. Betz AL: Alterations in cerebral endothelial cell function in ischemia In Advances in Neurology (Eds. Siesjo B, Wieloch T.), p. 301–313. New York: Raven Press, 1996. [PubMed] [Google Scholar]
  • 81. Siesjö BK, Katsura K, Mellergård P, Ekholm A, Lundgren J, Smith M‐L: Acidosis‐related brain damage In Progress in Brain Research (Eds. Kogure K, Hossmann K‐A, Siesjo BK.), p. 23–48. Amsterdam, Netherlands: Elsevier Science, 1993. [PubMed] [Google Scholar]
  • 82. Siesjö BK, Katsura KI, Krístián T, Li PA, Siesjö P: Molecular mechanisms of acidosis‐mediated damage. Acta Neurochir Suppl 1996; 66: 8–14 [DOI] [PubMed] [Google Scholar]
  • 83. Hossman K‐A: Thresholds of ischemic injury In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 193–204. Malden, Mass.: Black‐well Science, 1998. [Google Scholar]
  • 84. Tymianski M: The central role of calcium ions and calcium‐permeable channels in ischemic brain injury In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 371–390. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 85. Betz AL, Dietrich WD: Blood‐brain barrier dysfunction in cerebral ischemia In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 358–370. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 86. Choi DW: Glutamate neurotoxicity and disease of the nervous system. Neuron 1988; 1: 623–634 [DOI] [PubMed] [Google Scholar]
  • 87. Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor—still lethal after eight years. Trends Neurosci 1987; 10: 299–302 [DOI] [PubMed] [Google Scholar]
  • 88. Welsh FA: Ischemic energy failure In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 217–226. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 89. Back T, Nedergaard M, Ginsberg MD: The ischemic penumbra In Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management (Eds. Ginsberg M, Bogousslavsky J.), p. 276–286. Malden, Mass.: Blackwell Science, 1998. [Google Scholar]
  • 90. Takeda Y, Jacewicz M, Takeda Y, Nowak TS Jr, Pulsinelli WA: DC‐potential and energy metabolites in focal ischemia. J Cereb Blood Flow Metab 1993; 13 (suppl 1): S450 [Google Scholar]
  • 91. Back T, Hoehn‐Berlage M, Kohno K, Hossmann K‐A: Diffusion nuclear magnetic resonance imaging in experimental stroke: Correlation with cerebral metabolites. Stroke 1994; 25: 494–500 [DOI] [PubMed] [Google Scholar]
  • 92. Gyngell ML, Busch E, Schmitz B, Kohno K, Back T, Hoehn‐Berlage M, Hossmann K‐A: Evolution of acute focal cerebral ischemia in rats observed by localised 1H‐MRS, diffusion‐weighted MRI, and electrophysiological monitoring. NMR Biomed 1995; 8: 206–214 [DOI] [PubMed] [Google Scholar]
  • 93. Gyngell ML, Back T, Hoehn‐Berlage M, Kohno K, Hossmann K‐A: Transient cell depolarization after permanent middle cerebral artery occlusion: An observation by diffusion‐weighted MRI and localized 1H‐MRS. Magn Reson Med 1994; 31: 337–341 [DOI] [PubMed] [Google Scholar]
  • 94. Heiss W‐D, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K: Progressive derangement of peri‐infarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992; 12: 193–203 [DOI] [PubMed] [Google Scholar]
  • 95. Baron JC, Lebrun‐Grandie P, Collard P, Crouzel C, Mestelan G, Bousser MG: Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: Concise communication. J Nucl Med 1982; 23: 391–399 [PubMed] [Google Scholar]
  • 96. Lenzi GL, Jones T, McKenzie CG, Moss S: Non‐invasive regional study of chronic cerebrovascular disorders using the oxygen‐15 inhalation technique. J Neurol Neurosurg Psychiatry 1978; 41: 11–17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Frackowiak RSJ: Pathophysiology of human cerebral ischemia: studies with positron tomography and 15oxygen In Brain Imaging and Brain Function (Ed. Sokoloff L.), p. 139–161. New York: Raven Press, 1985. [PubMed] [Google Scholar]
  • 98. Baron JC, Rougement D, Lebrun‐Grandié P, Bousser MG, Cabanis E, Bories J, Comar D, Castaigne P: Measurement of local blood flow and oxygen consumption in evolving irreversible cerebral infarction: An in vivo study in man In Cerebral Vascular Disease, 4th ed. (Eds. Meyer JS, Lechner H, Reivich M, Ott EO.), p. 205–212. Princeton, N.J.: Excerpta Medica, 1983. [Google Scholar]
  • 99. Heiss W‐D, Grond M, Thiel A, Stockhausen H‐M, Rudolf J, Ghaemi M, Lottgen J, Stenzel C, Pawlik G: Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator throm‐bolysis of acute stroke. J Cereb Blood Flow Metab 1998; 18: 1298–1307 [DOI] [PubMed] [Google Scholar]
  • 100. Heiss W‐D, Kracht L, Grond M, Rudolf J, Bauer B, Wienhard K, Pawlik G: Early [11C] flumazenil/H2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke 2000; 31: 366–369 [DOI] [PubMed] [Google Scholar]
  • 101. Knight RA, Chopp M: Imaging techniques for focal ischemic damage In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 136–141. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 102. Dirnagl U: Measurements of microcirculatory events in the brain in vivo In Primer on Cerebrovascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 133–136. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 103. National Stroke Association : Stroke Statistics. Available at www.stroke.org/brain_stat.cfm. Accessed February 24, 2003.
  • 104. Sacco RL: Ischemic stroke In Handbook of Neuroepidemiology (Eds. Gorelick PB, Alter MA.), p. 77–119. New York: Marcel Dekker, 1994. [Google Scholar]
  • 105. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction: A population‐based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50: 208–216 [DOI] [PubMed] [Google Scholar]
  • 106. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Anti‐thrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119: 300S–320S [DOI] [PubMed] [Google Scholar]
  • 107. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13 [DOI] [PubMed] [Google Scholar]
  • 108. SALT Collaborative Group : Swedish Aspirin Low‐dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cere‐brovascular ischaemic events. Lancet 1991; 338: 1345–1349 [PubMed] [Google Scholar]
  • 109. Ticlopidine Aspirin Stroke Study Group : Ticlopidine versus aspirin for stroke prevention: On‐treatment results from the ticlopidine aspirin stroke study. J Stroke Cerebrovasc Dis 1993; 3: 169–176 [DOI] [PubMed] [Google Scholar]
  • 110. Mehta SR, Yusuf S, CURE Study Investigators : The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: Rationale, design and baseline characteristics including a meta‐analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033–2041 [DOI] [PubMed] [Google Scholar]
  • 111. CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339 [DOI] [PubMed] [Google Scholar]
  • 112. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL: Supplement to the guidelines for the management of transient ischemic attacks. A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999; 30: 2502–2511 [DOI] [PubMed] [Google Scholar]
  • 113. Bennett CL, Weinberg PD, Rozenberg‐Ben‐Dror K, Yarnold PR, Kwaan HC, Green D: Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases. Ann Intern Med 1998; 128: 541–544 [DOI] [PubMed] [Google Scholar]
  • 114. Taylor DW, Barnett HJM, Hayes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes R, Spence JD, for the ASA and Carotid Endarterectomy (ACE) Trial Colloborators : Low‐dose and high‐dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. Lancet 1999; 353: 2179–2184 [DOI] [PubMed] [Google Scholar]
  • 115. Eisert WG: Dipyridamole In Platelets (Ed. Michelson AD.), p. 803–815. San Diego, Calif.: Academic Press, 2002. [Google Scholar]
  • 116. Takehara K, Igarashi A, Ishibashi Y: Dipyridamole specifically decreases platelet derived growth factor release from platelets. Thromb Res 1990; 12 (suppl): 73–79 [DOI] [PubMed] [Google Scholar]
  • 117. Takehara K, Grotendorst GR, Silver R, LeRoy EC: Dipyridamole decreases platelet‐derived growth factor levels in human serum. Arteriosclerosis 1987; 7: 152–155 [DOI] [PubMed] [Google Scholar]
  • 118. The ESPS Group : The European Stroke Prevention Study (ESPS): Principal end‐points. Lancet 1987; 2: 1351–1354 [PubMed] [Google Scholar]
  • 119. Rajagopalan S, Harrison DG: Reversing endothelial dysfunction with ACE inhibitors. Circulation 1996; 94: 240–243 [DOI] [PubMed] [Google Scholar]
  • 120. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO‐HOPE substudy. Lancet 2000; 355: 253–259 [PubMed] [Google Scholar]
  • 121. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium‐channel blocker vs. diuretic: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALL‐HAT). J Am Med Assoc 2002; 288: 2981–2997 [DOI] [PubMed] [Google Scholar]
  • 122. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention. J Am Med Assoc 2002; 288: 1388–1398 [DOI] [PubMed] [Google Scholar]
  • 123. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group : Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–1687 [DOI] [PubMed] [Google Scholar]
  • 124. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C‐r, Liu C‐h, Alaupovic P, Kwong‐Fu H, Azen SP: Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized, controlled clinical trial. Ann Intern Med 1996; 124: 548–556 [DOI] [PubMed] [Google Scholar]
  • 125. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MPS, Nilsson J, Pachinger O, Weidinger F: HMG‐CoA reductase inhibitors regulate inflammatory transcription factors in human en‐dothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58–63 [DOI] [PubMed] [Google Scholar]
  • 126. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DGM, Guyer KE, Bates ER: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug‐drug interaction. Circulation 2003; 107: 32–37 [DOI] [PubMed] [Google Scholar]
  • 127. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, Colling C, Eskridge J, Deykin D, Winn HR, for the Veterans Affairs Cooperative Studies Program 309 Trialist Group : Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. J Am Med Assoc 1991; 266: 3289–3294 [PubMed] [Google Scholar]
  • 128. Cohen SN: Carotid endarterectomy for asymptomatic disease. J Stroke Cerebrovasc Dis 1997; 6: 180–184 [DOI] [PubMed] [Google Scholar]
  • 129. Vitek JJ, Roubin GS, Al‐Mubarek N, New G, Iyer SS: Carotid artery stenting: Technical considerations. Am J Neuroradiol 2002; 21: 1736–1743 [PMC free article] [PubMed] [Google Scholar]
  • 130. Gomez CR, Misra VK, Liu MW, Wadlington VR, Terry JB, Tulyapronchote R, Campbell MS: Elective stenting of symptomatic basilar artery stenosis. Stroke 2000; 31: 95–99 [DOI] [PubMed] [Google Scholar]
  • 131. Mori T, Kazita K, Chokyu K, Mima T, Mori K: Short‐term arterio‐graphic and clinical outcome after cerebral angioplasty and stenting for intracranial vertebrobasilar and carotid atherosclerotic occlusive disease. Am J Neuroradiol 2000; 21: 249–254 [PMC free article] [PubMed] [Google Scholar]
  • 132. Schneck MJ: Anticoagulation for stroke prevention In The Prevention of Stroke (Eds. Gorelick PB, Alter M.), p. 208–221. New York, N.Y.: Parthenon Publishing, 2002. [Google Scholar]
  • 133. Devuyst G, Bogousslavsky J: Status of patent foramen ovale, atrial septal aneurysm, atrial septal defect and aortic arch atheroma as risk factors for stroke. Neuroepidemiology 1997; 16: 217–223 [DOI] [PubMed] [Google Scholar]
  • 134. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators : Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–2631 [DOI] [PubMed] [Google Scholar]
  • 135. Zivin JA: Emerging treatments for stroke In Primer on Cerebro‐vascular Diseases (Eds. Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B.), p. 791–793. San Diego, Calif.: Academic Press, 1997. [Google Scholar]
  • 136. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA: Intravenous tissue‐type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. J Am Med Assoc 2000; 283: 1145–1150 [DOI] [PubMed] [Google Scholar]
  • 137. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD: Early intravenous throm‐bolysis for acute ischemic stroke in a community‐based approach. Stroke 1998; 29: 1544–1549 [DOI] [PubMed] [Google Scholar]
  • 138. Hachinski AV, Hill MD, Buchan AM: The Canadian Activase for Stroke Effectiveness Study (CASES): Final results (abstr). Cere‐brovasc Dis 2002; 13 (suppl 3): 99 [Google Scholar]
  • 139. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC: Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000; 31: 77–81 [DOI] [PubMed] [Google Scholar]
  • 140. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F, for the PROACT (Prolyse in Acute Cerebral Thromboembolism) Investigators : Intra‐arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. J Am Med Assoc 1999; 282: 2003–2011 [DOI] [PubMed] [Google Scholar]
  • 141. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P, for the Warfarin‐Aspirin Recurrent Stroke Study Group : A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES